Exhibit 10.2
THIRD AMENDMENT TO
INVESTOR RIGHTS AGREEMENT
This THIRD AMENDMENT, dated as of November 5, 2018 (this “Amendment”), to the Investor Rights Agreement, dated as of September 11, 2017 (as it may be amended from time to time, the “Investor Rights Agreement”), is entered into between Oncobiologics, Inc., a Delaware corporation (the “Company”), and BioLexis Pte. Limited, a Singapore private limited company (formerly known as GMS Tenshi Holdings Pte. Limited, the “Investor” and, collectively with the Company, the “Parties”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Investor Rights Agreement.
WHEREAS, the Company and the Investor entered into the Investor Rights Agreement;
WHEREAS, Section 8.7 of the Investor Rights Agreement permits the Parties to amend the Investor Rights Agreement by an instrument in writing signed on behalf of the Company and the Investor;
WHEREAS, the Company and Investor are entering into that certain Purchase Agreement, dated as of the date hereof (the “Nov 2018 Purchase Agreement”), pursuant to which, subject to the terms and conditions contained therein, Investor will purchase from the Company, and the Company will issue to Investor, the Shares (as defined therein); and
WHEREAS, in connection therewith, the Company and the Investor desire to further amend the Investor Rights Agreement as provided herein.
NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements contained herein, and intending to be legally bound hereby, the Company and the Investor hereby agree as follows:
1. Amendment of definition of Common Shares in the Investor Rights Agreement. Notwithstanding the amended definition found in the Second Amendment to the Investor Rights Agreement, the definition of “Common Shares” in Article VIII of the Investor Rights Agreement is hereby amended and restated as follows: “means the Preferred Shares, the Series A-1 Preferred (including the New Preferred, as each term is defined in the Exchange Agreement), and shares of Common Stock issuable upon conversion of the Preferred Shares, the Series A-1 Preferred (including the Conversion Shares, as such term is defined in the Exchange Agreement) and exercise of the Warrants, together with any shares of Common Stock (including, as each term is defined in the 2018 Purchase Agreement and in the Nov 2018 Purchase Agreement, as the case may be, the Common Shares, Shares, Warrants and Warrant Shares) otherwise held by the Shareholder, any Affiliate Shareholder and any Transferee Shareholder at any time following the date of this Agreement”.
2. Representations and Warranties. Each of the Company and the Investor represents and warrants that (a) it has the corporate power and authority to execute and deliver this Amendment and (b) this Amendment constitutes the legal, valid and binding obligation of each of the above parties, enforceable against each such party in accordance with its terms, subject to the Enforceability Exceptions.
| 1 |
3. Amendment of Section 8.2 (Fees and Expenses) of the Investor Rights Agreement. Section 8.2 of the Investor Rights Agreement is hereby amended and restated in its entirety as follows:
“Fees and Expenses. All costs and expenses incurred by the Parties in connection with the negotiation, execution and delivery of this Agreement, the Purchase Agreement, the Nov 2018 Purchase Agreement and any amendments relating thereto, and any costs and expenses, including advisor and attorney fees, incurred by Investor in connection with its ownership of any securities of the Company, including the Common Shares and the Warrants, will be borne solely and entirely by the Company, and the Company shall pay or reimburse Investor for all such amounts within ten (10) Business Days of receipt of an invoice relating thereto.”
4. No Other Modification. The Investor Rights Agreement shall not be modified by this Amendment in any respect except as expressly set forth herein.
5. Miscellaneous.Sections 8.5 (Interpretation; Headings),8.6 (Severability),8.7 (Entire Agreement; Amendments),8.13 (Waiver),8.8 (Assignment; No Third Party Beneficiaries),8.10 (Governing Law; Consent to Jurisdiction; Waiver of Jury Trial) and8.11 (Counterparts) of the Investor Rights Agreement are hereby incorporated into this Amendmentmutatis mutandis as if set forth in full herein.
[Remainder of page intentionally left blank]
| 2 |
IN WITNESS WHEREOF, the Company and the Investor have caused this Amendment to be executed as of the date first written above by their respective officers thereunto duly authorized.
| ONCOBIOLOGICS, INC. | |||
| By: | /s/ Lawrence A. Kenyon | ||
| Name: | Lawrence A. Kenyon | ||
| Title: | Chief Executive Officer and | ||
| Chief Financial Officer | |||
[THIRD AMENDMENT TO INVESTOR RIGHTS AGREEMENT SIGNATURE PAGE]
| BIOLEXISE PTE. LIMITED | |||
| By: | /s/ Faisal Sukhtian | ||
| Name: | Faisal Sukhtian | ||
| Title: | Director | ||
[THIRD AMENDMENT TO INVESTOR RIGHTS AGREEMENT SIGNATURE PAGE]